Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathilde Hunault

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
American Journal of Hematology|January 6, 2023
Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow TransplantationGuillermo Ortí, Luuk Gras, Nienke Zinger, et al.
Leukemia|April 21, 2023
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemiaNicolas Duployez, Loïc Vasseur, Rathana Kim, et al.
Blood|March 22, 2022
Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALLMarie Passet, Rathana Kim, Stéphanie Gachet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2018
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO TrialArnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, et al.
Hemasphere|June 17, 2026
<i>CEBP</i> and <i>ZEB2</i> alterations define three distinct subtypes of B-cell acute lymphoblastic leukemiaRathana Kim, Marie Passet, Hugo Bergugnat, et al.
European Journal of Haematology|November 19, 2019
Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWPPatrick J Hayden, Simona Iacobelli, José Antonio Pérez-Simón, et al.
Bone Marrow Transplantation|November 13, 2021
Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working partyJohannes Schetelig, Patrice Chevallier, Michel van Gelder, et al.
Bone Marrow Transplantation|October 2, 2020
Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working partyJohannes Schetelig, Patrice Chevallier, Michel van Gelder, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, et al.
Cancer Medicine|December 9, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapyLouise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
American Journal of Hematology|January 6, 2023
Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow TransplantationGuillermo Ortí, Luuk Gras, Nienke Zinger, et al.
Leukemia|April 21, 2023
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemiaNicolas Duployez, Loïc Vasseur, Rathana Kim, et al.
Blood|March 22, 2022
Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALLMarie Passet, Rathana Kim, Stéphanie Gachet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2018
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO TrialArnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, et al.
Hemasphere|June 17, 2026
<i>CEBP</i> and <i>ZEB2</i> alterations define three distinct subtypes of B-cell acute lymphoblastic leukemiaRathana Kim, Marie Passet, Hugo Bergugnat, et al.
European Journal of Haematology|November 19, 2019
Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWPPatrick J Hayden, Simona Iacobelli, José Antonio Pérez-Simón, et al.
Bone Marrow Transplantation|November 13, 2021
Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working partyJohannes Schetelig, Patrice Chevallier, Michel van Gelder, et al.
Bone Marrow Transplantation|October 2, 2020
Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working partyJohannes Schetelig, Patrice Chevallier, Michel van Gelder, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, et al.
Cancer Medicine|December 9, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapyLouise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, et al.
Pageof 13